Skip to main content
. 2022 Oct 15;11(6):2205–2217. doi: 10.1007/s40121-022-00703-y

Table 3.

Primary outcome: COVID-19-positive incidence rates during follow-up

Event BCG group (incidence rates) Placebo group (incidence rates) p value Odds ratio 95% CI
Definite COVID-19 infection (CB-NAAT-positive cases) 18 (7.3%) 17 (6.8%) 0.862 1.08 0.54–2.14
Probable COVID-19 infection (symptom screening) 15 (6.1%) 36 (14.5%) 0.003 0.38 0.20–0.72